Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Redhill Biopharma Ltd. RDHL

Healthcare  —  Drug Manufacturers Specialty & Generic
0.50 (0.02) (3.85%) as of 25 Sep
Market cap
$3.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Redhill Biopharma Ltd. (RDHL) Business Profile

Updated before January 2025

Company Overview

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on the development and commercialization of innovative, proprietary drugs for the treatment of gastrointestinal (GI) diseases and infectious diseases. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill has established itself as a key player in the biopharmaceutical sector. The company was co-founded by Dror Ben-Asher, who currently serves as the Chairman and Chief Executive Officer. Other key members of the leadership team include Micha Ben Chorin, the Chief Financial Officer, and Adi Frish, the Chief Corporate and Business Development Officer. RedHill operates globally, with a strong presence in the United States, where it conducts much of its commercial and clinical activities.

Core Business Segments

RedHill Biopharma focuses on two primary business segments: gastrointestinal (GI) diseases and infectious diseases. The company’s portfolio includes both commercial-stage products and a robust pipeline of late-stage clinical candidates.

Gastrointestinal (GI) Diseases

RedHill’s flagship products in the GI segment include:

  • Talicia®: A proprietary, FDA-approved treatment for Helicobacter pylori (H. pylori) infection, a major cause of peptic ulcers and gastric cancer. Talicia® is designed to address the growing issue of antibiotic resistance.
  • Movantik®: A treatment for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Movantik® is a key revenue driver for RedHill in the U.S. market.
  • Aemcolo®: An FDA-approved antibiotic for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia coli (E. coli).

Infectious Diseases

RedHill is also actively involved in the development of therapies for infectious diseases, including:

  • Opaganib: A novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with potential applications in treating COVID-19, cancer, and inflammatory diseases.
  • RHB-107 (Upamostat): An oral protease inhibitor targeting multiple indications, including COVID-19 and other viral infections.

Business Model

RedHill Biopharma operates a hybrid business model that combines in-house drug development with strategic acquisitions and partnerships. The company generates revenue primarily through the commercialization of its FDA-approved products, such as Talicia®, Movantik®, and Aemcolo®. Additionally, RedHill invests heavily in research and development (R&D) to advance its pipeline of innovative therapies. By leveraging its proprietary technologies and expertise in GI and infectious diseases, RedHill aims to address unmet medical needs and create long-term value for stakeholders.

The company also collaborates with leading academic institutions, research organizations, and pharmaceutical companies to accelerate the development and commercialization of its products. This collaborative approach enables RedHill to mitigate risks and optimize resource allocation.

Strategic Direction

RedHill Biopharma is committed to expanding its product portfolio and geographic footprint. Key strategic priorities include:

  • Pipeline Advancement: RedHill is focused on advancing its late-stage clinical candidates, including Opaganib and RHB-107, to address high-priority medical needs.
  • Commercial Expansion: The company aims to strengthen its presence in the U.S. market while exploring opportunities in Europe, Asia, and other regions.
  • Sustainability Goals: RedHill is dedicated to promoting sustainable practices across its operations, including reducing its environmental footprint and ensuring ethical supply chain management.
  • New Product Categories: The company is exploring potential opportunities in adjacent therapeutic areas, such as oncology and immunology, to diversify its revenue streams.

Competitive Landscape

RedHill Biopharma operates in a highly competitive environment, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Takeda Pharmaceuticals: A global leader in GI therapies, offering products such as Entyvio® for inflammatory bowel disease (IBD).
  • AbbVie: Known for its blockbuster drug Humira®, AbbVie is a major player in the GI and immunology markets.
  • Pfizer: A leading pharmaceutical company with a strong presence in infectious diseases and GI treatments.
  • Horizon Therapeutics: Focused on rare and rheumatic diseases, Horizon competes with RedHill in the GI space.

Despite the competitive landscape, RedHill differentiates itself through its focus on niche markets, innovative drug formulations, and a robust pipeline of late-stage candidates.

Risk Factors

RedHill Biopharma faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its key products, such as Talicia® and Movantik®. Any decline in sales or market share could adversely affect revenue.
  • Regulatory Challenges: The biopharmaceutical industry is subject to stringent regulatory requirements, which could delay or prevent product approvals.
  • Supply Chain Disruptions: RedHill’s operations depend on a reliable supply chain for raw materials and manufacturing. Disruptions could impact product availability.
  • Competition: Intense competition from larger pharmaceutical companies and emerging biotech firms poses a significant risk.
  • Clinical Trial Risks: The success of RedHill’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.

Recent Developments

RedHill Biopharma has made significant progress in recent years, including:

  • COVID-19 Research: The company has been actively involved in developing treatments for COVID-19, with Opaganib and RHB-107 showing promising results in clinical trials.
  • Commercial Milestones: RedHill has expanded the market reach of Talicia® and Movantik®, achieving strong sales growth in the U.S.
  • Partnerships: The company has entered into strategic collaborations to enhance its R&D capabilities and accelerate product development.
  • Regulatory Approvals: RedHill continues to pursue regulatory approvals for its pipeline candidates in multiple jurisdictions.

Investment Considerations

Investors considering RedHill Biopharma should weigh the following factors:

Strengths

  • Diverse Portfolio: RedHill’s portfolio includes FDA-approved products and a robust pipeline of late-stage candidates.
  • Market Focus: The company’s focus on GI and infectious diseases addresses significant unmet medical needs.
  • Innovation: RedHill leverages proprietary technologies to develop novel therapies.
  • Growth Potential: The company’s strategic initiatives position it for long-term growth.

Risks

  • Financial Performance: RedHill has yet to achieve consistent profitability, which may concern risk-averse investors.
  • Regulatory Hurdles: Delays in product approvals could impact the company’s growth trajectory.
  • Market Competition: Intense competition from established players poses a challenge.

Conclusion

RedHill Biopharma Ltd. is a dynamic biopharmaceutical company with a strong focus on GI and infectious diseases. With a diverse portfolio of FDA-approved products and a promising pipeline, RedHill is well-positioned to address unmet medical needs and drive long-term growth. However, the company faces significant risks, including market competition and regulatory challenges. Overall, RedHill represents a compelling investment opportunity for those seeking exposure to the biopharmaceutical sector, particularly in niche therapeutic areas.